Tempus AI — Blitz Index 55 (C)
A+B+C = 69 clears the 65 line on its own — then D −14 drags it to 55. Organic diagnostics +31.2%, gross margin up 22.1pp in four years.
Confidence: High · Category: platforms
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 18 / 25 | FY2025 +83.4% headline, but 62.7% of the increase is Ambry — organic diagnostics still +31.2% |
| B · Moat | 39 / 60 | Data flywheel: 8.6M de-identified records; 19 of the top 20 pharma as customers; $1.1B+ remaining TCV |
| C · Creative destruction | 12 / 15 | Intelligent Diagnostics replacing single-analyte tests; just-in-time trial network built on real-time data |
| D · BlitzFailing | −14 | Lefkofsky 57.9% vote + CEO-chair; related-party revenue surge; debt-to-equity 4.3x |
Radar axes (0–100): Moat 65 · Speed 72 · Creative 80.
Watch item
Gates: G1 ✓ · G2 ✓. 10 points below the threshold — first score. One point below the FLAG watch line: the data blitz faces its monetization test.
Strengths
- FY2026 revenue guidance $1.595–1.605B (~+25%) and adjusted EBITDA guidance ~+$65M
- Gross margin 40.6% to 62.7% in four years — the best margin trajectory measured
- 19 of the top 20 pharma as customers, $1.1B+ remaining TCV — data business demand visibility
- 87% physician 12-month retention on 55%+ oncologist penetration
Concerns
- Lefkofsky: 57.9% voting power + CEO-chair plus $35M mutual payment structure with co-founded Pathos
- Related-party revenue $4.5M to $65.3M in one year — the biggest question mark on revenue quality
- Collection rates of 50–55% — half of tests start as receivables
- Trials revenue down three straight years; debt-to-equity 4.3x plus a $500M ATM overhang
More Platforms companies
Other Platforms names on the Blitz Index, highest score first: Alphabet (82/A), Meta (78/B), Snowflake (76/B).
Next earnings
Nov 2, 2026 · Before open · Confirmed
Coverage
Tempus AI, Inc. · Q3 2026 due Nov 2, 2026 (BMO, confirmed) · Score 55 · Grade C
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.